Amir Toor, M.D. - Faculty Profile

Biography

Amir Toor, M.D., is a Professor in the Department of Internal Medicine at UT Southwestern Medical Center and a member of its Division of Hematology and Oncology. He specializes in autologous and allogeneic stem cell transplantation and cellular immunotherapy for hematological malignancies, graft-versus-host disease, and transplant immunology.

Dr. Toor earned his medical degree at King Edward Medical University in Lahore, Pakistan. He completed a residency in internal medicine at UConn Health and its affiliated hospitals and gained advanced training through a hematology, oncology, and bone marrow transplantation fellowship at the University of Minnesota Medical Center.

Certified by the American Board of Internal Medicine in hematology and internal medicine, he joined the UT Southwestern faculty in 2025. He previously served as medical director of the Stem Cell Transplant and Cellular Therapy Program at the Lehigh Valley Health Network’s Topper Cancer Institute in Allentown, Pennsylvania. Prior to that, he held faculty appointments at Virginia Commonwealth University in Richmond, Virginia, Loyola University Medical Center in Maywood, Illinois, and the University of Arkansas in Little Rock.

His research interests include optimizing immune recovery following donor stem cell transplantation, preventing cancer relapse, mathematical modeling of immune system recovery following stem cell transplantation, and the biology of blood cancers.

Dr. Toor has delivered numerous presentations and published more than 100 abstracts and more than 90 peer-reviewed academic articles related to his areas of expertise.

Personal Note

When he’s not at work, Dr. Toor enjoys gardening, reading books on physics, and spending time with his family.

Education

Medical School: King Edward Medical College, Pakistan (1990)
Internship: Flushing Hospital Medical Center (1993), Internal Medicine
Residency: University of Connecticut Health Center (1996), Internal Medicine
Fellowship: University of Minnesota (1999), Hematology Oncology

Publications

Featured Publications

Understanding Telomere Biology in Hematopoietic Cell Transplantation: A Dynamical Systems Perspective: Amir A. Toor, Morgan Horton, Haniya Khalid, Elizabeth Krieger, Tsung-Po Lai, Stephen R. Spellman, John E. Levine, Wael Saber, Abraham Aviv, Valerie Stewart, Shahinaz M Gadalla Medrxiv 2025
Feasibility of intravenous vitamin C supplementation in allogeneic hematopoietic cell transplant recipients.: Simmons GL, Sabo R, Qayyum R, Aziz M, Martin E, Bernard RJ, Sriparna M, McIntire C, Krieger E, Brophy DF, Natarajan R, Iii AF, Roberts CH, Toor A, EJHaem 2024 Oct 5 5 1043-1047
SARS-CoV-2 Vaccination in the First Year After Hematopoietic Cell Transplant or Chimeric Antigen Receptor T-Cell Therapy: A Prospective, Multicenter, Observational Study.: Hill JA, Martens MJ, Young JH, Bhavsar K, Kou J, Chen M, Lee LW, Baluch A, Dhodapkar MV, Nakamura R, Peyton K, Howard DS, Ibrahim U, Shahid Z, Armistead P, Westervelt P, McCarty J, McGuirk J, Hamadani M, DeWolf S, Hosszu K, Sharon E, Spahn A, Toor AA, Waldvogel S, Greenberger LM, Auletta JJ, Horowitz MM, Riches ML, Perales MA, Clin Infect Dis 2024 Aug 79 2 542-554
Increased donor inhibitory KIR are associated with reduced GVHD and improved survival following HLA-matched unrelated donor HCT in paediatric acute leukaemia.: Krieger E, Qayyum R, Toor A, Br J Haematol 2024 May 204 5 1935-1943
Defining and Grading Infections in Clinical Trials Involving Hematopoietic Cell Transplantation: A Report From the BMT CTN Infectious Disease Technical Committee.: Shahid Z, Etra AM, Levine JE, Riches ML, Baluch A, Hill JA, Nakamura R, Toor AA, Ustun C, Young JH, Perales MA, Epstein DJ, Murthy HS, Transplant Cell Ther 2024 May 30 5 540.e1-540.e13
Differential Antibody Response To Polysaccharide Vaccines Following Allogeneic Stem Cell Transplantation; A Dynamical Systems Perspective: Viktoriya Zelikson, Maheen Khan, Morgan Horton, Thuy Ho, Catherine Roberts, Amir Toor 2024
Cell-free next-generation sequencing impacts diagnosis and antimicrobial therapy in immunocompromised hosts: A retrospective study.: Vissichelli NC, Morales MK, Kolipakkam B, Bryson A, Sabo RT, Toor AA, Transpl Infect Dis 2023 Feb 25 1 e13954
High dose valacyclovir for cytomegalovirus prophylaxis following allogeneic hematopoietic cell transplantation.: Hawks KG, Fegley A, Sabo RT, Roberts CH, Toor AA, J Oncol Pharm Pract 2023 Jan 29 1 130-137
Allogeneic haematopoietic cell transplants as dynamical systems: influence of early-term immune milieu on long-term T-cell recovery.: Zelikson V, Sabo R, Serrano M, Aqeel Y, Ward S, Al Juhaishi T, Aziz M, Krieger E, Simmons G, Roberts C, Reed J, Buck G, Toor A, Clin Transl Immunology 2023 12 7 e1458
Dynamical Systems Modeling of Early-Term Immune Reconstitution with Different Antithymocyte Globulin Administration Schedules in Allogeneic Stem Cell Transplantation.: Zelikson V, Simmons G, Raman N, Krieger E, Rebiero A, Hawks K, Aziz M, Roberts C, Chesney A, Reed J, Gress R, Toor A, Transplant Cell Ther 2022 Feb 28 2 85.e1-85.e9

Honors & Awards

Distinguished Mentor Award, School of Medicine, Virginia Commonwealth University
(2021)
Outstanding Mentor Award, Department of Internal Medicine, Virginia Commonwealth University
(2017)
Distinguished Scholarship Award, Department of Internal Medicine, Virginia Commonwealth University
(2016)

Professional Associations/Affiliations

American Society of Transplant and Cellular Therapy